US generics company Mylan Inc. has obtained worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus products for asthma and COPD using Pfizer's proprietary dry powder inhalation technology. Pfizer will also allow Mylan to develop and commercialize other DPI products using the … [Read more...] about Mylan gets Pfizer’s respiratory delivery platform, acquires global rights to generic Diskus products
Business
Catalent joins IPAC-RS
CRO Catalent Pharma Solutions has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), a consortium of companies involved in the development, manufacture, and marketing of OINDPs, whose mission is "to advance scientifically driven approaches to enhancing product quality of inhaled and intranasal drug products." Other IPAC-RS … [Read more...] about Catalent joins IPAC-RS
Novartis warns of delays in US approval process for NVA237 and QVA149
In its third quarter results for 2011, Novartis announced that, "In the US, NVA237 will require additional clinical data to support submission and thus will be delayed." Furthermore, the company warned, "The changes to the US NVA237 program will similarly impact approval timing for QVA149 in the US where additional clinical studies will be required. The QVA149 … [Read more...] about Novartis warns of delays in US approval process for NVA237 and QVA149
New scientific advisory board for Prosonix
Ken Cunningham, who recently joined the board of UK pharmaceutical and particle engineering company Prosonix, will lead the company's new scientific advisory board. Joining Cunningham on Prosonix's SAB are: Peter Barnes, Professor of Thoracic Medicine and Head of Airway Disease, National Heart and Lung Institute, and Honorary Consultant Physician, Royal Brompton … [Read more...] about New scientific advisory board for Prosonix
Acton Pharmaceuticals will develop and market Nasacort HFA in US
Massachusetts respiratory pharmaceutical company Acton Pharmaceuticals has entered into a licensing agreement with Sanofi US that gives Acton exclusive US rights to develop and market prescription Nasacort HFA triamcinolone acetonide nasal aerosol for the treatment of nasal allergy symptoms due to seasonal or perennial rhinitis in adults and children 6 years old and … [Read more...] about Acton Pharmaceuticals will develop and market Nasacort HFA in US
Impel gets new funding for development of intranasal delivery
Impel NeuroPharma has announced new funding for development of its Pressurized Olfactory Delivery (POD) device from a variety of sources. The company says that in addition to closing on over a half million dollars of equity investment from "angel investors experienced in the pharmaceutical and medical device industries," it has also entered into collaborations with … [Read more...] about Impel gets new funding for development of intranasal delivery
Hovione and Bend agree to collaborate on inhalation technologies, manufacturing
Two experts in particle manufacturing for inhaled dry powder formulations, Hovione and Bend research, have entered into a non-exclusive collaboration in which they will have access to each other's technologies. The partnership also gives Bend access to Hovione's commercial manufacturing capabilities in Portugal, Ireland, China, and the US. “Hovione has world-class … [Read more...] about Hovione and Bend agree to collaborate on inhalation technologies, manufacturing
Insight recalls lot of Nostrilla nasal decongestant spray
Insight Pharmaceuticals has voluntarily recalled a single lot of its Nostrilla oxymetazoline hydrochloride nasal spray due to possible contamination with Burkholderia cepacia bacteria. Nostrilla is available without prescription, and lot #11G075, which consisted of 34,092 1/2-oz bottles, was distributed in US retail stores and pharmacies. According to Insight, it has … [Read more...] about Insight recalls lot of Nostrilla nasal decongestant spray
Perrigo files an ANDA for a generic Patanase nasal spray; Alcon files suit
According to Perrigo, Alcon Labs has filed a patent infringement suit in the United States District Court for the Northern District of Texas after Perrigo filed an abbreviated new drug application (ANDA) for a generic version of Alcon's Patanase olopatadine hydrochloride nasal spray. The FDA approved Alcon's NDA for Patanase for the treatment of seasonal allergic … [Read more...] about Perrigo files an ANDA for a generic Patanase nasal spray; Alcon files suit
Some acetylcysteine inhalation solution now available
According to the FDA, American Regent/Luitpold has now released several batches of acetylcysteine inhalation solution, including 10 ml vials of both 100 mg/ml and 200 mg/ml solutions and 30 ml vials of the 200 mg/ml solution. The company's facility in Shirley, NY was closed in April 2011 due to safety concerns. Two other manufacturers, Roxanne Laboratories and … [Read more...] about Some acetylcysteine inhalation solution now available